• Prothena highlighted partnered late-stage programs, led by Roche’s Phase 3 prasinezumab trial in early Parkinson’s disease, with primary completion expected in 2029.
• Novo Nordisk’s coramitug (PRX004) in ATTR cardiomyopathy remains in Phase 3, with CLEOPATTRA ongoing and primary completion expected in 2029.
• Bristol Myers Squibb-linked PRX019 completed Phase 1; Prothena flagged a potential $55 million milestone tied to a development decision by year-end 2026.
• Prothena also pointed to up to $105 million in clinical milestones by year-end 2026, including a $50 million Phase 3 enrollment milestone for coramitug.
• Shareholder returns included $22.3 million of repurchases in the first half of 2026 under a program authorizing up to $100 million through Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.